pitavastatin has been researched along with thiazolyl-blue* in 1 studies
1 other study(ies) available for pitavastatin and thiazolyl-blue
Article | Year |
---|---|
Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins.
In the present study, we examined the mechanisms underlying the cytotoxicity of pitavastatin, a new statin, and we compared the in vitro potencies of muscle cytotoxicity using a prototypic embryonal rhabdomyosarcoma cell line (RD cells), a typical side effect of statins and compared the cholesterol-lowering effects of statins using Hep G2 hepatoma cells. Pitavastatin reduced the number of viable cells and caused caspase-9 and -3/7 activation in a time- and concentration-dependent manner. The comparison of cytotoxities of statins showed that statins significantly reduced cell viability and markedly enhanced activity of caspase-3/7 in concentration-dependent manner. On the other hand, the effects of hydrophilic statins, pravastatin, rosuvastatin were very weak. The rank order of cytotoxicity was cerivastatin > simvastatin acid> fluvastatin > atorvastatin > lovastatin acid > pitavastatin >> rosuvastatin, pravastatin. Statin-induced cytotoxicity is associated with these partition coefficients. On the other hand, the cholesterol-lowering effect of statins did not correlate with these partition coefficients and cytotoxicity. Thus, it is necessary to consider the association between risk of myopathy and cholesterol-lowering effect of a statin for precise use of statins. Topics: Anticholesteremic Agents; Caspases; Cell Line, Tumor; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Quinolines; Tetrazolium Salts; Thiazoles | 2008 |